HABA Laboratories, Inc. (4925) AI Stock Analysis

• Market Cap: ¥6.84B
• Dividend Yield: 2.38%
• Average Volume (3M): 2.14K
• Price to Earnings (P/E): 10.2
• Beta (1Y): 0.27
• Revenue Growth: -0.79%
• EPS Growth: N/A
• Country: JP
• Employees: 631
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 34.53
• Shares Outstanding: 3,935,000
• 10 Day Avg. Volume: 2,940
• 30 Day Avg. Volume: 2,136
• PEG Ratio: -0.09
• Price to Book (P/B): 0.74
• Price to Sales (P/S): 0.55
• P/FCF Ratio: 4.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ¥1,780.00 ▲(7.23% Upside)
• Action: Reiterated Date: 10/01/25
• Date: Action: Reiterated 10/01/25

HABA Laboratories scores a 63, driven primarily by its strong valuation metrics, including a low P/E ratio and attractive dividend yield. While financial performance shows resilience in balance sheet strength, challenges in revenue growth and profitability weigh on the score. Technical analysis indicates mixed signals, with short-term bearish momentum but potential longer-term support.

Positive Factors

Balance sheet strength

HABA's strong equity base and low leverage provide a durable financial cushion. Low debt-to-equity reduces refinancing and solvency risk, supporting capital allocation for operations, dividends or selective investment over the next several months even if revenue remains pressured.

Improving operating cash flow

Recent improvement in operating cash flow indicates better cash conversion from core operations. That enhances short-to-medium term liquidity, supports working capital and discretionary spending, and partially offsets prior free cash flow volatility when sustaining operations or funding initiatives.

Robust gross margins

Sustained strong gross margins point to effective pricing or cost control in core product lines. This structural margin buffer helps absorb revenue softness, supports operating leverage recovery, and preserves capacity to invest in marketing or product development to stabilize growth.

Negative Factors

Declining revenue trend

A negative revenue growth trend reduces scale and puts pressure on fixed-cost absorption. Persistent top-line contraction constrains reinvestment, weakens negotiating leverage with suppliers, and makes it harder to restore margins and earnings, posing a sustained medium-term growth risk.

Volatile profitability

Significant swings in net income and erratic EBIT/EBITDA margins indicate unstable operating performance. This unpredictability complicates planning, capital allocation and dividend policy, and suggests structural issues in demand, pricing, or cost control that may persist absent strategic fixes.

Inconsistent free cash flow growth

Struggles to grow free cash flow historically reduce flexibility for investments, debt reduction and shareholder returns. Even with recent OCF improvement, inconsistent FCF undermines confidence in sustainable internal funding and creates execution risk over the next several quarters.

HABA Laboratories, Inc. Business Overview & Revenue Model

Company Description

HABA Laboratories,Inc. manufactures and sells skin care, and hair and body care products in Japan and internationally. Its skin care products include cleansers/face washes, toners, special care products, and squalane oils; and hair and body care products comprise shampoos, conditioners, soaps, and hair and hand treatment products. The company sells its products through mail order, shops, drug/variety stores, and internet. It has approximately 70 HABA shops located in department stores, shopping malls, etc. HABA Laboratories,Inc. was founded in 1983 and is headquartered in Tokyo, Japan.

How the Company Makes Money

HABA Laboratories, Inc. generates revenue primarily through the sale of its laboratory products, which include diagnostic kits, reagents, and specialized laboratory instruments. The company operates on a business-to-business model, where it sells its products to healthcare providers, research institutions, and pharmaceutical companies. Key revenue streams include direct sales, long-term contracts with laboratories, and partnerships with other biotech firms for co-development projects. HABA also benefits from government contracts and grants aimed at supporting innovative healthcare solutions, which contribute significantly to its earnings. Additionally, the company explores international markets, expanding its customer base and diversifying its revenue through global partnerships.

HABA Laboratories, Inc. Financial Statement Overview

Summary

HABA Laboratories shows a mixed financial picture. The income statement is pressured by revenue declines and inconsistent profitability, while the balance sheet remains strong with low leverage and solid equity. Cash flow generation is improving, but historical volatility presents challenges. The company demonstrates resilience in its financial stability but needs to address profitability and growth concerns.

Income Statement

HABA Laboratories has faced challenges with revenue growth, showing an overall declining trend from the 2020 peak. The gross profit margin remains robust, suggesting efficient cost management, but net income has fluctuated significantly, impacting net profit margins negatively in recent years. The EBIT and EBITDA margins have been erratic, reflecting operational challenges and inconsistent profitability.

Balance Sheet

The balance sheet shows strong equity with a favorable equity ratio, indicating financial stability. The debt-to-equity ratio is low, reducing leverage risks. However, the return on equity is unstable due to fluctuating net income. Overall, the company maintains a solid asset base with a strong equity cushion.

Cash Flow

Cash flow analysis reveals improving operating cash flow in the most recent period, which is a positive sign. Yet, the company has struggled with free cash flow growth, and previous periods showed volatility. The operating cash flow to net income ratio indicates better cash generation relative to profits recently, but historical instability remains a concern.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	12.02B	12.06B	12.32B	12.04B	12.91B	14.31B
Gross Profit	8.08B	7.99B	8.03B	8.17B	8.79B	10.20B
EBITDA	826.86M	811.56M	-1.31B	17.05M	448.30M	960.14M
Net Income	638.78M	576.57M	-2.12B	-707.87M	-269.03M	216.42M
Balance Sheet
Total Assets	11.76B	12.34B	12.43B	14.66B	15.69B	17.44B
Cash, Cash Equivalents and Short-Term Investments	4.48B	4.74B	3.96B	4.82B	5.65B	5.66B
Total Debt	1.56B	1.82B	2.36B	2.03B	2.56B	3.92B
Total Liabilities	2.95B	3.42B	3.92B	3.88B	4.05B	5.40B
Stockholders Equity	8.82B	8.93B	8.51B	10.77B	11.64B	12.04B
Cash Flow
Free Cash Flow	0.00	1.48B	-1.02B	-232.69M	1.53B	-346.95M
Operating Cash Flow	0.00	1.62B	-587.92M	55.96M	1.71B	534.71M
Investing Cash Flow	0.00	-147.18M	-441.79M	-214.40M	-216.49M	-925.08M
Financing Cash Flow	0.00	-689.49M	171.06M	-676.32M	-1.51B	825.38M

HABA Laboratories, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1660.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Positive. The current price of 1660 is below the 20-day moving average (MA) of 1778.95, below the 50-day MA of 1739.80, and below the 200-day MA of 1702.76, indicating a bullish trend. The MACD of 29.73 indicates Negative momentum. The RSI at 61.50 is Neutral, neither overbought nor oversold. The STOCH value of 75.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4925.

HABA Laboratories, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4933	71 Outperform	¥19.30B	7.69	―	0.91%	13.12%	27.53%
4918	68 Neutral	¥2.29B	6.59	―	―	12.96%	―
4920	68 Neutral	¥2.40B	10.17	―	1.72%	-6.06%	-97.12%
4925	63 Neutral	¥6.84B	10.15	―	2.38%	-0.79%	―
4936	63 Neutral	¥8.80B	23.17	―	2.65%	11.87%	-31.02%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
4926	58 Neutral	¥5.82B	24.36	―	1.68%	8.46%	―